The Increasing Value Of The Liquid Biopsy Market By 2035

The global Liquid Biopsy Market is valued at USD 11.41 Billion in 2024 and is projected to reach a value of USD 30.65 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 9.41% between 2025 and 2035.

The Liquid Biopsy Market refers to a revolutionary, non-invasive diagnostic method used to detect cancer cell fragments, DNA, or biomarkers in body fluids like blood, urine, or saliva. Unlike traditional tissue biopsies, liquid biopsies offer a swift, repeatable, and minimally invasive approach for early cancer detection, monitoring treatment response, and identifying potential relapses. The market has witnessed strong momentum driven by rising global cancer incidences, increasing emphasis on personalized medicine, technological innovations in genomics and molecular diagnostics, and a growing preference for precision oncology by healthcare providers. Additionally, the demand is further fueled by clinical advantages such as real-time tumor monitoring, early-stage cancer detection, and ease of integration into routine check-ups, which collectively have positioned liquid biopsy as a transformative solution in modern diagnostics.

Our comprehensive Liquid Biopsy Market report is ready with the latest trends, growth opportunities, and strategic analysis- View Sample Report PDF

Market Segmentation

By Product & Services

• Assay Kits (52.5%)
• Instruments
• Services

By Circulating Biomarkers

• Circulating Tumor Cells
• Circulating Tumor DNA (ctDNA)
• Circulating Tumor DNA (ctDNA)
• Cell-free DNA (cfDNA) (46.5%)
• Extracellular Vesicles (EVS)
• Other Circulating Biomarkers

By Clinical Applications

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring

By Technology

• Multi-Gene Parallel Analysis using NGS (76.2%)
• Single-Gene Analysis using PCR Microarrays

By Application

• Cancer Applications ( 85.1%)

•    Lung Cancer
•    Breast Cancer
•    Colorectal Cancer
•    Prostate Cancer
•    Melanoma
•    Other Cancers

• Non-Cancer Applications

•     Non-Invasive Prenatal Testing (NIPT)
•     Organ Transplantations
•     Infectious Disease Testing

By Sample Type

• Blood (68.1%)
• Other Sample Types

By End User

• Reference Laboratories
• Hospitals & Physician Laboratories (43.1%)
• Academic & Research Centers
• Other End Users

By Region

• North America (46.2%)
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Market Dynamics

The liquid biopsy market dynamics are influenced by a combination of technological evolution, clinical needs, and regulatory advancements. As the global burden of cancer continues to grow, there is an urgent necessity for accurate, rapid, and minimally invasive diagnostic methods, giving liquid biopsies a competitive edge over conventional tissue biopsy techniques. Healthcare systems worldwide are moving toward value-based care, and liquid biopsies play an essential role in this shift by reducing diagnostic delays and improving long-term patient outcomes through timely therapeutic decisions.

The market is also being shaped by active investment and strategic partnerships among biotech companies, diagnostic firms, and research institutions. These collaborations are accelerating commercial adoption, enhancing R&D, and enabling scalable innovations in next-generation sequencing (NGS), circulating tumor DNA (ctDNA) analysis, and CTC (circulating tumor cell) detection. Furthermore, regulatory bodies such as the FDA have taken significant strides in streamlining approval pathways and assigning breakthrough designations to promising liquid biopsy technologies, which boost investor confidence and lower entry barriers. On the downside, pricing pressures, limited reimbursement frameworks in some countries, and challenges related to clinical validation of liquid biopsy tests can impact the growth rate. However, the overarching demand for real-time, less-invasive, and patient-centric diagnostic methods continues to dominate and define the market’s trajectory.

Market Key Companies  

• Bio-Rad Laboratories
• Biocept Inc.
• Guardant Health
• Illumina Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V.

• Thermo Fisher Scientific Inc

To Get a Customized List of Companies Please Click Here: https://www.vantagemarketresearch.com/liquid-biopsy-market-2009/request-sample

Top Trends

Among the most influential trends reshaping the liquid biopsy market is the expansion of multi-cancer early detection (MCED) tests, which can detect multiple types of cancer in one test using a single blood sample. These tests, powered by artificial intelligence and big data analytics, are anticipated to redefine preventive diagnostics by detecting cancer even before symptoms arise. Another powerful trend is the integration of liquid biopsy in companion diagnostics (CDx), where the technology is used to guide treatment decisions, particularly in immuno-oncology and targeted therapy regimes. This alignment with personalized medicine is helping clinicians select the most effective treatment based on the patient’s unique cancer profile.

There is also a growing trend toward non-oncology applications, notably in transplant monitoring and prenatal testing, which broadens the commercial scope of liquid biopsy beyond oncology. Moreover, increased interest in point-of-care liquid biopsy devices aims to bring diagnostic capabilities directly into clinical settings, enabling quicker decision-making and improved patient engagement. The market is also seeing a surge in strategic mergers, acquisitions, and funding, as companies vie for technological leadership in key platforms such as next-gen sequencing and cfDNA (cell-free DNA) extraction. Lastly, the rise of direct-to-consumer (DTC) testing services, combined with growing patient literacy and demand for proactive health management, is expected to create a broader, consumer-driven opportunity in this landscape.

Market Developments

• In 2025, Labcorp announced the expansion of announced the expansion of its precision oncology portfolio with two new offerings. The first is Labcorp Plasma Detect, a clinical test designed to help evaluate the risk of disease recurrence in patients with stage III colon cancer. The second is PGDx elio plasma focus Dx, the first and only FDA-authorized kitted liquid biopsy test for pan-solid tumors, which supports the identification of patients who may be eligible for targeted therapies.
• In 2025, Natera, Inc. (US) launched its ultra-sensitive Signatera Genome-MRD test in the US.
• In 2025, Tempus AI, Inc. announced the launch of its FDA-approved next-generation sequencing (NGS)-based in vitro diagnostic test, xT CDx. The test is available to all ordering clinicians across the U.S. xT CDx provides comprehensive genomic insights through one of the largest FDA-approved gene panels currently on the market.
• In 2025, Myriad Genetics, Inc. (US) collaborated with Gabbi (US), a telehealth solution for breast cancer risk assessment & specialist care services. The companies will collaborate to provide an integrated offering that combines Gabbi’s risk assessment program and access to breast specialists with Myriad’s MyRisk with RiskScore Hereditary Cancer Test.
• In 2024, QIAGEN opened its regional headquarters in Saudi Arabia and signed an MoU with the Ministry of Health of Saudi Arabia to support public health initiatives.

Top Report Findings

• The global Liquid Biopsy Market is valued at USD 11.41 Billion in 2024 and is projected to reach a value of USD 30.65 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 9.41% between 2025 and 2035.
• Cancer diagnosis and monitoring remain the dominant segment, accounting for over 75% of market share.
• Circulating tumor DNA (ctDNA) is the most frequently analyzed biomarker due to its high accuracy and reliability.
• North America led global revenue generation in 2023, with the U.S. alone contributing over 60% of the regional income.
• Next-generation sequencing (NGS) platforms are rapidly being adopted in academic and hospital labs for liquid biopsy analysis.
• Companies offering multi-cancer detection solutions are attracting significant venture capital and strategic investment.
• A notable trend is the regulatory simplification and increased number of FDA approvals for liquid biopsy assays.
• Key players in the market include Guardant Health, Exact Sciences Corporation, Illumina Inc., and Qiagen N.V.

Challenges

Despite its immense promise, the liquid biopsy market is not without its set of challenges. One of the primary barriers is clinical validation and standardization. Since liquid biopsies are based on relatively new molecular techniques, their sensitivity and specificity vary across different applications and platforms, often leading to inconsistent results. Healthcare providers may be hesitant to rely solely on these diagnostics without conclusive clinical guidelines or standardized procedures. Additionally, reimbursement issues remain a significant constraint in certain regions. Insurance coverage is limited or varies widely based on geography and type of test, making access to these diagnostics uneven.

Another key challenge revolves around the interpretation of results, especially in asymptomatic patients or early-stage diseases, where distinguishing between benign and malignant biomarker signatures can be complex. High operational costs related to advanced technologies such as NGS, along with training requirements for laboratory professionals, add to the practical obstacles. Moreover, data privacy concerns, especially in DTC liquid biopsy testing, also raise ethical and legal questions that need to be carefully addressed to ensure patient trust and widespread adoption.

Opportunities

On the flip side, the opportunities in the liquid biopsy market are vast and multifaceted. There's a tremendous chance to expand the use of liquid biopsies in preventative care and population-wide screening programs. Early detection through liquid biopsy not only improves cancer survival rates but also reduces healthcare costs by avoiding late-stage treatments. This evolution from reactive medicine to proactive care could transform healthcare delivery models, especially in developed nations. Another rich opportunity exists within collaborative diagnostics, especially in precision oncology, where liquid biopsy tests are paired with pharmaceuticals to monitor therapeutic effectiveness and resistance.

Emerging markets present untapped opportunities for key players to establish early market access through affordable testing kits and portable diagnostic devices. By tailoring solutions to resource-constrained environments, companies can contribute to global cancer control while expanding their footprint. Further, technological integration with AI, machine learning, and predictive analytics in real-time diagnostics paves the way for personalized, traceable, and highly responsive care delivery. As more extensive clinical trials validate the efficacy of liquid biopsy across diseases and populations, the prospect for wider insurance coverage and regulatory support becomes more tangible, creating a scalable path ahead for the industry at large.

Key Questions Answered in the Report

1. What is the current size of the global liquid biopsy market, and what is its projected growth through 2030?
2. What are the key drivers contributing to the rising popularity of liquid biopsy over traditional biopsy techniques?
3. Which biomarkers (ctDNA, cfDNA, exosomes, etc.) are most commonly analyzed in liquid biopsy platforms?
4. What are the main technological trends shaping the future of the liquid biopsy industry?
5. Who are the major clinical end users of liquid biopsy tests oncologists, researchers, or general healthcare providers?
6. What role does North America play in the growth of the liquid biopsy market?
7. How are companies overcoming regulatory and reimbursement hurdles to increase adoption?
8. In what ways are liquid biopsies expanding beyond oncology into broader diagnostic applications?

Expanding Market Need: Access Our Full Report for In-Depth Analysis and Trends!

Regional Analysis: Focus on North America

North America represents the most lucrative region in the liquid biopsy market, accounting for a dominant share of the global revenue. The United States, in particular, exhibits a strong demand for advanced diagnostics owing to well-established healthcare infrastructure, robust insurance systems, and higher disposable incomes. The region benefits considerably from being home to several leading biotech firms and research institutions, accelerating innovation and R&D in the field. Companies like Guardant Health, Thermo Fisher Scientific, Exact Sciences, and Illumina are not only headquartered in North America but are also at the forefront of pioneering liquid biopsy technologies, including next-generation sequencing and ctDNA analysis.

Federal agencies like the FDA have played a pivotal role in granting accelerated approval and breakthrough designations to promising liquid biopsy solutions, thus fostering market growth. Additionally, increasing collaborations between academic research centers and diagnostics companies have led to the development of clinically validated and commercially viable assay kits. North America also benefits from widespread awareness campaigns surrounding early cancer detection and genetic screening programs, which have elevated the public’s receptiveness to preventive diagnostics.

Furthermore, supportive healthcare policies, structured reimbursement frameworks, and progressive clinical guidelines have made it easier for medical professionals to adopt liquid biopsy as part of regular diagnostic protocols. With ongoing investments in infrastructure, AI integration into diagnostic pipelines, and a growing patient population seeking personalized and non-invasive testing options, North America is poised to retain its leadership in the global liquid biopsy marketplace for years to come.